EMA Authorised: Vizimpro (dacomitinib monohydrate) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Vizimpro (dacomitinib monohydrate) for non-small cell lung cancer, with Pfizer Europe MA EEIG as the marketing authoriz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• VIZIMPRO (dacomitinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Pfizer Europe MA EEIG. Decision date: 11/12/2024